DPDoctor's PassportEducation
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
RapidMLAMSRAGP

Periorificial dermatitis

Essential points for quick revision.

Synopsis

Recognise papular inflammation around the mouth, nose and eyes, identify corticosteroid and product drivers, distinguish acne, rosacea and infection, and use low-burden withdrawal and anti-inflammatory treatment safely.

  • Look for grouped 1–2 mm papules, papulovesicles or pustules around mouth, nose or eyes, often with dry sensitive skin and a narrow spared strip beside the lip vermilion.
  • Absence of comedones helps separate periorificial dermatitis from acne; persistent diffuse centrofacial flushing and telangiectasia favour rosacea.
  • Ask specifically about prescribed, borrowed and over-the-counter topical corticosteroids, transfer from hands, inhalers, nasal sprays, cosmetics and heavy facial products.

Key red flags

Eye pain, photophobia or reduced vision; honey-coloured crust with spreading infection; vesicles with ocular proximity; rapid facial swelling; fever; scarring; or a fixed photosensitive or granulomatous eruption requires urgent or specialist diagnostic review.

Ocular warning departure

Eye pain, photophobia, reduced vision or corneal abnormality is not uncomplicated periocular skin disease and needs urgent ophthalmic assessment.

Investigation priorities

01
Complete topical and inhaled exposure inventoryFirst step

Find direct, transferred and aerosolised corticosteroid exposure and other potentially aggravating products.

Management branches

Exposure withdrawalBreak the corticosteroid cycle

Typical periorificial lesions occur during direct or indirect facial corticosteroid exposure.

  1. Explain the association and possible temporary rebound, then stop an unnecessary facial corticosteroid; a supervised short taper with low-potency treatment is reserved for selected prolonged misuse rather than automatic continuation.
  2. Retain essential inhaled or intranasal treatment, coordinate with its prescriber, optimise device or spacer technique and wash or rinse exposed perioral skin after use.

Key medicines

Metronidazole 0.75% creamApply a thin layer to affected periorificial skin twice daily for a planned four-to-six-week trial, keeping it out of the eyes, lips and mucosa.
Lymecycline 408 mg capsulesTake one capsule orally once daily for a defined four-to-six-week off-label course when systemic treatment is indicated.
Open full textbook Answer 2 questions
Sources and review status5 sources · checked 27 Aug 2026 · clinical review pending
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom